Minimum Dose CT Post Lung Biopsy
Can Minimum Dose CT Post Lung Biopsy Predict Patient Outcome?
1 other identifier
interventional
100
1 country
1
Brief Summary
The aim is to evaluate whether Minimum Dose CT (MnDCT) is useful in the management of patients post Lung Biopsy
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_1 lung-cancer
Started Jan 2004
Shorter than P25 for phase_1 lung-cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2004
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2005
CompletedFirst Submitted
Initial submission to the registry
September 12, 2005
CompletedFirst Posted
Study publicly available on registry
September 16, 2005
CompletedApril 23, 2007
September 1, 2005
September 12, 2005
April 20, 2007
Conditions
Outcome Measures
Primary Outcomes (1)
Detection of Pneumothorax
Interventions
Eligibility Criteria
You may qualify if:
- All Patients having a lung biopsy
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Toronto General Hospital
Toronto, Ontario, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Narinder Paul, FRCP C
University Health Network, Toronto
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
September 12, 2005
First Posted
September 16, 2005
Study Start
January 1, 2004
Study Completion
September 1, 2005
Last Updated
April 23, 2007
Record last verified: 2005-09